{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:35:45Z","timestamp":1793367345855,"version":"4.5.0"},"reference-count":221,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002954","name":"Universit\u00e0 degli Studi di Milano-Bicocca","doi-asserted-by":"publisher","award":["CUP E63C22002170007"],"award-info":[{"award-number":["CUP E63C22002170007"]}],"id":[{"id":"10.13039\/501100002954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.biopha.2025.118044","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:48:03Z","timestamp":1744206483000},"page":"118044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases"],"prefix":"10.1016","volume":"186","author":[{"given":"Ramona","family":"Meanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bresciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3709-6574","authenticated-orcid":false,"given":"Laura","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Coco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Omeljaniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Torsello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118044_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1213\/ANE.0000000000006472","article-title":"The Basic Science of Cannabinoids","volume":"138","author":"Sideris","year":"2024","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.biopha.2025.118044_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12079-021-00622-6","article-title":"Endocannabinoid signaling pathways: beyond CB1R and CB2R","volume":"15","author":"Biringer","year":"2021","journal-title":"J. Cell Commun. Signal"},{"key":"10.1016\/j.biopha.2025.118044_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An Introduction to the Endogenous Cannabinoid System","volume":"79","author":"Lu","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118044_bib5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2174\/092986710790980014","article-title":"From surface to nuclear receptors: the endocannabinoid family extends its assets","volume":"17","author":"Pistis","year":"2010","journal-title":"Curr. Med Chem."},{"key":"10.1016\/j.biopha.2025.118044_bib6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2174\/092986710790980078","article-title":"Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs","volume":"17","author":"Marzo","year":"2010","journal-title":"Curr. Med Chem."},{"key":"10.1016\/j.biopha.2025.118044_bib7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/sj.bjp.0705467","article-title":"Anandamide and vanilloid TRPV1 receptors","volume":"140","author":"Ross","year":"2003","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41401-018-0075-x","article-title":"Brain activity of anandamide: a rewarding bliss?","volume":"40","author":"Scherma","year":"2019","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.biopha.2025.118044_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/08830185.2014.921165","article-title":"Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease","volume":"34","author":"Sido","year":"2015","journal-title":"Int Rev. Immunol."},{"key":"10.1016\/j.biopha.2025.118044_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-662-46450-2_7","article-title":"The role of the endocannabinoid system in pain","volume":"227","author":"Woodhams","year":"2015","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaci.2023.09.043","article-title":"Cannabinoid receptor 2 as a regulator of inflammation induced oleoylethanolamide in eosinophilic asthma","volume":"153","author":"Kwon","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2025.118044_bib12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.coph.2004.05.007","article-title":"The gastrointestinal pharmacology of cannabinoids: an update","volume":"4","author":"Coutts","year":"2004","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/can.2017.0015","article-title":"N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities","volume":"2","author":"Grabiec","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.biopha.2025.118044_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/1440-1681.13238","article-title":"A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-\u03b1, on the management and prevention of obesity","volume":"47","author":"Tutunchi","year":"2020","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"10.1016\/j.biopha.2025.118044_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/19390211.2021.2005733","article-title":"Palmitoylethanolamide: A Potential Alternative to Cannabidiol","volume":"20","author":"Clayton","year":"2023","journal-title":"J. Diet. Suppl."},{"key":"10.1016\/j.biopha.2025.118044_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bjp.0707481","article-title":"Novel cannabinoid receptors","volume":"152","author":"Brown","year":"2007","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib17","unstructured":"The Human Protein Atlas, (n.d.). \u3008https:\/\/www.proteinatlas.org\/\u3009 (accessed September 12, 2024)."},{"key":"10.1016\/j.biopha.2025.118044_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118044_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejmech.2004.10.002","article-title":"Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study","volume":"40","author":"Montero","year":"2005","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118044_bib20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1042\/BST20221316","article-title":"Structural and functional insights into the G protein-coupled receptors: CB1 and CB2","volume":"51","author":"Brust","year":"2023","journal-title":"Biochem Soc. Trans."},{"key":"10.1016\/j.biopha.2025.118044_bib21","doi-asserted-by":"crossref","first-page":"9790","DOI":"10.1074\/jbc.M112.438804","article-title":"Distinct roles of \u03b2-arrestin 1 and \u03b2-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1)","volume":"288","author":"Ahn","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118044_bib22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/mol.111.074013","article-title":"Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands","volume":"81","author":"Atwood","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib23","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjp.0705529","article-title":"Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells","volume":"140","author":"Zoratti","year":"2003","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib24","doi-asserted-by":"crossref","first-page":"20851","DOI":"10.1074\/jbc.M111.335273","article-title":"Cannabinoid receptors CB1 and CB2 form functional heteromers in brain","volume":"287","author":"Call\u00e9n","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118044_bib25","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1074\/jbc.M115.712661","article-title":"Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression","volume":"291","author":"Coke","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118044_bib26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.biopha.2025.118044_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41401-019-0210-3","article-title":"Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow","volume":"40","author":"Wu","year":"2019","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.biopha.2025.118044_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neuroscience.2015.10.041","article-title":"Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus","volume":"311","author":"Li","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2025.118044_bib29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cns.13977","article-title":"Update on the controversial identity of cells expressing cnr2 gene in the nervous system","volume":"29","author":"Grabon","year":"2023","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.biopha.2025.118044_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/glia.24280","article-title":"Endocannabinoid signaling in the central nervous system","volume":"71","author":"Martinez Ramirez","year":"2023","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2025.118044_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1567-5769(01)00147-3","article-title":"Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation","volume":"2","author":"Carlisle","year":"2002","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.biopha.2025.118044_bib32","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1523\/JNEUROSCI.23-04-01398.2003","article-title":"Nonpsychotropic cannabinoid receptors regulate microglial cell migration","volume":"23","author":"Walter","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1471-4159.2005.03380.x","article-title":"Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli","volume":"95","author":"Maresz","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2025.118044_bib34","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1046\/j.1460-9568.2003.02704.x","article-title":"Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models","volume":"17","author":"Zhang","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/glia.20084","article-title":"Cannabinoid signaling in glial cells","volume":"48","author":"Stella","year":"2004","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2025.118044_bib36","article-title":"The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation","volume":"12","author":"Young","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbi.2015.06.002","article-title":"Endocannabinoids drive the acquisition of an alternative phenotype in microglia","volume":"49","author":"Mecha","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.biopha.2025.118044_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108555","article-title":"The cannabinoid system and microglia in health and disease","volume":"190","author":"Duffy","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118044_bib39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fncel.2019.00424","article-title":"The Endocannabinoid System as a Window Into Microglial Biology and Its Relationship to Autism","volume":"13","author":"Araujo","year":"2019","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/biom10091228","article-title":"Gene Expression Analysis of Astrocyte and Microglia Endocannabinoid Signaling during Autoimmune Demyelination","volume":"10","author":"Moreno-Garc\u00eda","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118044_bib41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/glia.24281","article-title":"Endocannabinoid signaling in microglia","volume":"71","author":"Marinelli","year":"2023","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2025.118044_bib42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bbi.2017.10.021","article-title":"Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization","volume":"68","author":"Braun","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.biopha.2025.118044_bib43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fimmu.2017.00112","article-title":"Inflammatory Regulation by Driving Microglial M2 Polarization: Neuroprotective Effects of Cannabinoid Receptor-2 Activation in Intracerebral Hemorrhage","volume":"8","author":"Lin","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118044_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107657","article-title":"A comprehensive review of the multifaceted role of cannabinoid receptor type 2 in neurodegenerative and neuropsychiatric disorders","volume":"213","author":"Garc\u00eda-Guti\u00e9rrez","year":"2025","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2025.118044_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105226","article-title":"CB2 receptor in the CNS: From immune and neuronal modulation to behavior","volume":"150","author":"Grabon","year":"2023","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.biopha.2025.118044_bib46","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/bph.12607","article-title":"Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice","volume":"171","author":"Zoppi","year":"2014","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib47","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.3390\/cells10123548","article-title":"The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson\u2019s Disease","volume":"10","author":"Yu","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118044_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108538","article-title":"Cannabinoid CB2 receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice","volume":"189","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118044_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuint.2011.11.012","article-title":"The inhibitory action of exo- and endocannabinoids on [3H]GABA release are mediated by both CB\u2081and CB\u2082receptors in the mouse hippocampus","volume":"60","author":"And\u00f3","year":"2012","journal-title":"Neurochem. Int"},{"key":"10.1016\/j.biopha.2025.118044_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22139","article-title":"D2 autoreceptor switches CB2 receptor effects on [3H]-dopamine release in the striatum","volume":"74","author":"L\u00f3pez-Ram\u00edrez","year":"2020","journal-title":"Synapse"},{"key":"10.1016\/j.biopha.2025.118044_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22061","article-title":"Presynaptic cannabinoid CB2 receptors modulate [3H]-Glutamate release at subthalamo-nigral terminals of the rat","volume":"72","author":"S\u00e1nchez-Zavaleta","year":"2018","journal-title":"Synapse"},{"key":"10.1016\/j.biopha.2025.118044_bib52","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/acer.12845","article-title":"Effects of Chronic Alcohol Exposure on the Modulation of Ischemia-Induced Glutamate Release via Cannabinoid Receptors in the Dorsal Hippocampus","volume":"39","author":"Zheng","year":"2015","journal-title":"Alcohol Clin. Exp. Res"},{"key":"10.1016\/j.biopha.2025.118044_bib53","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1073\/pnas.1118167109","article-title":"Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors","volume":"109","author":"den Boon","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118044_bib54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.neuropharm.2018.07.020","article-title":"Cannabinoid type 2 receptors mediate a cell type-specific self-inhibition in cortical neurons","volume":"139","author":"Stumpf","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118044_bib55","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.neuron.2016.03.034","article-title":"Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus","volume":"90","author":"Stempel","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2025.118044_bib56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/glia.20108","article-title":"Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes","volume":"49","author":"Sheng","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2025.118044_bib57","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ajpath.2012.11.024","article-title":"Activation of cannabinoid CB2 receptor-mediated AMPK\/CREB pathway reduces cerebral ischemic injury","volume":"182","author":"Choi","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2025.118044_bib58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejmech.2013.11.026","article-title":"Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer\u2019s disease","volume":"73","author":"Gonz\u00e1lez-Naranjo","year":"2014","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118044_bib59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2017.05.044","article-title":"Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer\u2019s disease","volume":"811","author":"Wu","year":"2017","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neubiorev.2018.12.026","article-title":"Progress in brain cannabinoid CB2 receptor research: From genes to behavior","volume":"98","author":"Jordan","year":"2019","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.biopha.2025.118044_bib61","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/S0952523800171093","article-title":"Expression of CB2 cannabinoid receptor mRNA in adult rat retina","volume":"17","author":"Lu","year":"2000","journal-title":"Vis. Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib62","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1476-5381.2010.00729.x","article-title":"CB2: a cannabinoid receptor with an identity crisis","volume":"160","author":"Atwood","year":"2010","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib63","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjp.0707527","article-title":"The peripheral cannabinoid receptor knockout mice: an update","volume":"153","author":"Buckley","year":"2008","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0014-2999(00)00211-9","article-title":"Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor","volume":"396","author":"Buckley","year":"2000","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib65","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fphar.2018.00632","article-title":"Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes","volume":"9","author":"Navarro","year":"2018","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104518","article-title":"Somatostatin and cannabinoid receptors crosstalk in protection of huntingtin knock-in striatal neuronal cells in response to quinolinic acid","volume":"129","author":"Zou","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.biopha.2025.118044_bib67","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fphar.2017.00516","article-title":"Interaction between Cannabinoid Type 1 and Type 2 Receptors in the Modulation of Subventricular Zone and Dentate Gyrus Neurogenesis","volume":"8","author":"Rodrigues","year":"2017","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5093493","article-title":"Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson\u2019s Disease","volume":"2020","author":"Wi","year":"2020","journal-title":"J. Immunol. Res"},{"key":"10.1016\/j.biopha.2025.118044_bib69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1139\/cjpp-2016-0346","article-title":"Cannabinoid signaling in health and disease","volume":"95","author":"Lu","year":"2017","journal-title":"Can. J. Physiol. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib70","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System","volume":"19","author":"Zou","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118044_bib71","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.3390\/ijms21207693","article-title":"Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases","volume":"21","author":"Haspula","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118044_bib72","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/ACO.0000000000000616","article-title":"An overview of the cannabinoid type 2 receptor system and its therapeutic potential","volume":"31","author":"Bie","year":"2018","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/j.biopha.2025.118044_bib73","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13167-020-00203-4","article-title":"Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies","volume":"11","author":"Reddy","year":"2020","journal-title":"EPMA J."},{"key":"10.1016\/j.biopha.2025.118044_bib74","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1021\/acschemneuro.0c00551","article-title":"Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands","volume":"11","author":"Yang","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib75","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","article-title":"Updated research nosology for HIV-associated neurocognitive disorders","volume":"69","author":"Antinori","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2025.118044_bib76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrn2040","article-title":"HIV and antiretroviral therapy in the brain: neuronal injury and repair","volume":"8","author":"Ellis","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib77","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1473-3099(13)70269-X","article-title":"HIV-associated neurocognitive disorder","volume":"13","author":"Clifford","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118044_bib78","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13365-017-0556-6","article-title":"Changing clinical phenotypes of HIV-associated neurocognitive disorders","volume":"24","author":"Sacktor","year":"2018","journal-title":"J. Neurovirol"},{"key":"10.1016\/j.biopha.2025.118044_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251944","article-title":"Quality of life in people living with HIV-associated neurocognitive disorder: A scoping review study","volume":"16","author":"Alford","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118044_bib80","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/COH.0000000000000287","article-title":"Persistent HIV-1 replication during antiretroviral therapy","volume":"11","author":"Martinez-Picado","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.biopha.2025.118044_bib81","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fcimb.2019.00362","article-title":"Microglial Cells: The Main HIV-1 Reservoir in the Brain","volume":"9","author":"Wallet","year":"2019","journal-title":"Front Cell Infect. Microbiol"},{"key":"10.1016\/j.biopha.2025.118044_bib82","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tins.2020.06.007","article-title":"The Paradox of HIV Blood-Brain Barrier Penetrance and Antiretroviral Drug Delivery Deficiencies","volume":"43","author":"Osborne","year":"2020","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib83","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s11481-011-9291-6","article-title":"Cannabinoids inhibit migration of microglial-like cells to the HIV protein Tat","volume":"6","author":"Fraga","year":"2011","journal-title":"J. Neuroimmune Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/ijms22010019","article-title":"CB2 Receptor in Microglia: The Guardian of Self-Control","volume":"22","author":"Komorowska-M\u00fcller","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118044_bib85","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2990.2011.01177.x","article-title":"Cannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities","volume":"37","author":"Cosenza-Nashat","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.biopha.2025.118044_bib86","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1523\/JNEUROSCI.3923-04.2005","article-title":"A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis","volume":"25","author":"Benito","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib87","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjp.0707505","article-title":"Cannabinoid CB2 receptors in human brain inflammation","volume":"153","author":"Benito","year":"2008","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib88","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/mol.111.071647","article-title":"Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss","volume":"80","author":"Kim","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib89","first-page":"75","article-title":"HIV-1 envelope protein gp120 modulation of glutamate effects on cortical neuronal synapses: implications for HIV-1-associated neuropathogenesis","volume":"15","author":"Liu","year":"2023","journal-title":"Int J. Physiol. Pathophysiol. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib90","first-page":"79","article-title":"The impact of cannabinoids on inflammasome signaling in HIV-1 infection","volume":"2","author":"Min","year":"2023","journal-title":"NeuroImmune Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.118044_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.590201","article-title":"\u03b2-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19","volume":"12","author":"Jha","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib92","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ibneur.2021.01.004","article-title":"Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review","volume":"10","author":"Aly","year":"2021","journal-title":"IBRO Neurosci. Rep."},{"key":"10.1016\/j.biopha.2025.118044_bib93","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.3390\/cells12141811","article-title":"Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoir Markers in People with HIV on Antiretroviral Therapy: Results of the CTN PT028 Pilot Clinical Trial","volume":"12","author":"Mboumba Bouassa","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118044_bib94","unstructured":"A.D. International, World Alzheimer Report 2023: Reducing Dementia Risk: Never too early, never too late, (2023). \u3008https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2023\/\u3009 (accessed September 13, 2024)."},{"key":"10.1016\/j.biopha.2025.118044_bib95","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/00207454.2013.833510","article-title":"Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer\u2019s disease","volume":"124","author":"Cai","year":"2014","journal-title":"Int J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib96","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2025.118044_bib97","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd1495","article-title":"The endocannabinoid system and its therapeutic exploitation","volume":"3","author":"Marzo","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118044_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.962922","article-title":"Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer\u2019s disease","volume":"16","author":"Coles","year":"2022","journal-title":"Front Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib99","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer\u2019s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ram\u00edrez","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1053680","article-title":"Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer\u2019s disease: A systematic review and meta-analysis of animal studies","volume":"14","author":"Kamaruzzaman","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib101","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2010.03.024","article-title":"The endocannabinoid system and amyloid-related diseases","volume":"224","author":"Ruiz-Valdepe\u00f1as","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2025.118044_bib102","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.3390\/ijms24076827","article-title":"The Cannabinoids, CBDA and THCA, Rescue Memory Deficits and Reduce Amyloid-Beta and Tau Pathology in an Alzheimer\u2019s Disease-like Mouse Model","volume":"24","author":"Kim","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118044_bib103","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13256-022-03457-w","article-title":"Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer\u2019s disease symptoms: a case report","volume":"16","author":"Ruver-Martins","year":"2022","journal-title":"J. Med Case Rep."},{"key":"10.1016\/j.biopha.2025.118044_bib104","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/1570159X16666180702144644","article-title":"Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer\u2019s Disease","volume":"17","author":"Talarico","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2025.118044_bib105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-2-29","article-title":"Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation","volume":"2","author":"Ehrhart","year":"2005","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2025.118044_bib106","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fnins.2016.00243","article-title":"CB2 Cannabinoid Receptor As Potential Target against Alzheimer\u2019s Disease","volume":"10","author":"Aso","year":"2016","journal-title":"Front Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib107","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12974-018-1174-9","article-title":"Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer\u2019s disease","volume":"15","author":"L\u00f3pez","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2025.118044_bib108","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","article-title":"CB2 receptor and amyloid pathology in frontal cortex of Alzheimer\u2019s disease patients","volume":"34","author":"Solas","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.biopha.2025.118044_bib109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s42238-022-00119-y","article-title":"Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review","volume":"4","author":"Bahji","year":"2022","journal-title":"J. Cannabis Res"},{"key":"10.1016\/j.biopha.2025.118044_bib110","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.3390\/ijms25074050","article-title":"Potential Therapeutic Targets to Modulate the Endocannabinoid System in Alzheimer\u2019s Disease","volume":"25","author":"Kanwal","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118044_bib111","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118044_bib112","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2174\/187152709789824642","article-title":"J. Fern\u00e1ndez-Ruiz, Cannabinoids and Parkinson\u2019s disease","volume":"8","author":"Garc\u00eda-Arencibia","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.biopha.2025.118044_bib113","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1089\/can.2023.0023","article-title":"Cannabinoids in Treating Parkinson\u2019s Disease Symptoms: A Systematic Review of Clinical Studies","volume":"8","author":"Varshney","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.biopha.2025.118044_bib114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5603\/PJNNS.a2022.0004","article-title":"Cannabis in Parkinson\u2019s Disease - the patient\u2019s perspective versus clinical trials: a systematic literature review","volume":"56","author":"Figura","year":"2022","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.biopha.2025.118044_bib115","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00702-019-02018-8","article-title":"Evidence for the use of cannabinoids in Parkinson\u2019s disease","volume":"126","author":"Buhmann","year":"2019","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.biopha.2025.118044_bib116","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.3390\/biomedicines10112986","article-title":"The Role of Cannabinoid Type 2 Receptors in Parkinson\u2019s Disease","volume":"10","author":"Basile","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118044_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.01310","article-title":"ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?","volume":"13","author":"Mejzini","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib118","article-title":"Potential Applications for Growth Hormone Secretagogues Treatment of Amyotrophic Lateral Sclerosis","author":"Meanti","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2025.118044_bib119","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/bph.15386","article-title":"Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis","volume":"178","author":"Rodr\u00edguez-Cueto","year":"2021","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/cns.12262","article-title":"Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(\u00ae) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis","volume":"20","author":"Moreno-Martet","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.biopha.2025.118044_bib121","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1471-4159.2006.04346.x","article-title":"The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset","volume":"101","author":"Shoemaker","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2025.118044_bib122","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1096\/fj.05-4743fje","article-title":"Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice","volume":"20","author":"Bilsland","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2025.118044_bib123","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/j.1471-4159.2004.02544.x","article-title":"Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice","volume":"89","author":"Witting","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2025.118044_bib124","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11481-015-9602-4","article-title":"Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders","volume":"10","author":"Espejo-Porras","year":"2015","journal-title":"J. Neuroimmune Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib125","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/bph.14216","article-title":"Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis","volume":"176","author":"Espejo-Porras","year":"2019","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib126","first-page":"551","article-title":"Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis","author":"Fern\u00e1ndez-Trapero","year":"2017","journal-title":"Dis. Model Mech. 10"},{"key":"10.1016\/j.biopha.2025.118044_bib127","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC Neurol."},{"key":"10.1016\/j.biopha.2025.118044_bib128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14660820310016813","article-title":"Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid","volume":"5","author":"Raman","year":"2004","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"10.1016\/j.biopha.2025.118044_bib129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neuropharm.2017.03.037","article-title":"Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS","volume":"124","author":"Pasquarelli","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118044_bib130","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2009.200642","article-title":"Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial","volume":"81","author":"Weber","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118044_bib131","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1872312811206020102","article-title":"Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis","volume":"6","author":"Joerger","year":"2012","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.biopha.2025.118044_bib132","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1474-4422(18)30406-X","article-title":"Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Riva","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2025.118044_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","article-title":"Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis","volume":"93","author":"Dutta","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2025.118044_bib134","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneurol.2015.222","article-title":"Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis","volume":"11","author":"Mandolesi","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.biopha.2025.118044_bib135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118044_bib136","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878323","article-title":"Progressive multiple sclerosis: latest therapeutic developments and future directions","volume":"12","author":"Faissner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.biopha.2025.118044_bib137","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib138","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pneurobio.2010.06.005","article-title":"Animal models of multiple sclerosis--potentials and limitations","volume":"92","author":"Mix","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2025.118044_bib139","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jnr.24224","article-title":"Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitis","volume":"96","author":"Bjelobaba","year":"2018","journal-title":"J. Neurosci. Res"},{"key":"10.1016\/j.biopha.2025.118044_bib140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196277","article-title":"Experimental autoimmune encephalomyelitis (EAE) up-regulates the mitochondrial activity and manganese superoxide dismutase (MnSOD) in the mouse renal cortex","volume":"13","author":"Packialakshmi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118044_bib141","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuron.2005.11.027","article-title":"The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells","volume":"49","author":"Eljaschewitsch","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2025.118044_bib142","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1093\/brain\/awm160","article-title":"The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis","volume":"130","author":"Centonze","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2025.118044_bib143","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jns.2009.07.021","article-title":"Plasma endocannabinoid levels in multiple sclerosis","volume":"287","author":"Jean-Gilles","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.biopha.2025.118044_bib144","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nbd.2005.03.002","article-title":"Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and\/or vanilloid receptors in a rat model of multiple sclerosis","volume":"20","author":"Cabranes","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2025.118044_bib145","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/jnnp.2007.139071","article-title":"Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis","volume":"79","author":"Di Filippo","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118044_bib146","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1523\/JNEUROSCI.4814-06.2007","article-title":"Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis","volume":"27","author":"Benito","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib147","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm1561","article-title":"Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells","volume":"13","author":"Maresz","year":"2007","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2025.118044_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2013.11.002","article-title":"Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS","volume":"287","author":"Kong","year":"2014","journal-title":"Cell Immunol."},{"key":"10.1016\/j.biopha.2025.118044_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105607","article-title":"Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB2R modulators in neurodegenerative diseases","volume":"170","author":"Ferrisi","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2025.118044_bib150","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2174\/1570159X18666200217140255","article-title":"Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders","volume":"18","author":"Estrada","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2025.118044_bib151","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35003583","article-title":"Cannabinoids control spasticity and tremor in a multiple sclerosis model","volume":"404","author":"Baker","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118044_bib152","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/j.1476-5381.2011.01414.x","article-title":"Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K\/Akt and the mammalian target of rapamycin (mTOR) pathways","volume":"163","author":"Gomez","year":"2011","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174398","article-title":"Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases","volume":"909","author":"Hashiesh","year":"2021","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib154","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.clinthera.2007.09.013","article-title":"Oromucosal delta9-tetrahydrocannabinol\/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial","volume":"29","author":"Rog","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2025.118044_bib155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1352458511419700","article-title":"A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex\u00ae (nabiximols)","volume":"18","author":"Notcutt","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.biopha.2025.118044_bib156","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00702-024-02750-w","article-title":"The pathobiology of depression in Huntington\u2019s disease: an unresolved puzzle","volume":"131","author":"Jellinger","year":"2024","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.biopha.2025.118044_bib157","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118044_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-71779-1_1","article-title":"Clinical Features of Huntington\u2019s Disease","volume":"1049","author":"Ghosh","year":"2018","journal-title":"Adv. Exp. Med Biol."},{"key":"10.1016\/j.biopha.2025.118044_bib159","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11910-024-01345-y","article-title":"Huntington\u2019s Disease: Latest Frontiers in Therapeutics","volume":"24","author":"Saade","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.biopha.2025.118044_bib160","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2967\/jnumed.110.077156","article-title":"Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo","volume":"51","author":"Laere","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2025.118044_bib161","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuint.2007.06.031","article-title":"Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6\/2 mice, a transgenic model of Huntington\u2019s disease","volume":"52","author":"Bisogno","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.biopha.2025.118044_bib162","doi-asserted-by":"crossref","unstructured":"C. Casteels, R. Ahmad, M. Vandenbulcke, W. Vandenberghe, K. Laere, Cannabinoids and Huntington\u2019s disease, (2015) 61\u201397. https:\/\/doi.org\/10.1016\/B978-0-12-417041-4.00004-7.","DOI":"10.1016\/B978-0-12-417041-4.00004-7"},{"key":"10.1016\/j.biopha.2025.118044_bib163","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1111\/febs.12329","article-title":"In vitro and in vivo models of Huntington\u2019s disease show alterations in the endocannabinoid system","volume":"280","author":"Bari","year":"2013","journal-title":"FEBS J."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2025.118044_bib164","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease","volume":"134","author":"Bl\u00e1zquez","year":"2011","journal-title":"Brain: A J. Neurol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118044_bib165","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2174\/1568007033482751","article-title":"The endocannabinoid system and Huntington\u2019s disease","volume":"2","author":"Lastres-Becker","year":"2003","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.biopha.2025.118044_bib166","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","article-title":"Neuroprotective properties of cannabigerol in Huntington\u2019s disease: studies in R6\/2 mice and 3-nitropropionate-lesioned mice","volume":"12","author":"Valdeolivas","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biopha.2025.118044_bib167","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2025.118044_bib168","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington\u2019s disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2025.118044_bib169","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease","volume":"263","author":"L\u00f3pez-Send\u00f3n Moreno","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.biopha.2025.118044_bib170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JHD-170283","article-title":"Cannabinoids for Treatment of Dystonia in Huntington\u2019s Disease","volume":"7","author":"Saft","year":"2018","journal-title":"J. Huntingt. Dis."},{"key":"10.1016\/j.biopha.2025.118044_bib171","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/157488912798842278","article-title":"Cannabinoids: novel medicines for the treatment of Huntington\u2019s disease","volume":"7","author":"Sagredo","year":"2012","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.biopha.2025.118044_bib172","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.47391\/JPMA.7805","article-title":"Therapeutic use of cannabinoids for the treatment of neurodegenerative disorders: a potential breakthrough","volume":"73","author":"Kumar","year":"2023","journal-title":"J. Pak. Med Assoc."},{"key":"10.1016\/j.biopha.2025.118044_bib173","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-3-030-57369-0_6","article-title":"Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s Diseases","volume":"1264","author":"P\u00e9rez-Olives","year":"2021","journal-title":"Adv. Exp. Med Biol."},{"key":"10.1016\/j.biopha.2025.118044_bib174","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1367-5931(03)00079-6","article-title":"Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system","volume":"7","author":"Cravatt","year":"2003","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.biopha.2025.118044_bib175","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.3390\/ijms23084407","article-title":"Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain","volume":"23","author":"Della Pietra","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118044_bib176","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s10194-022-01449-1","article-title":"Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine","volume":"23","author":"Greco","year":"2022","journal-title":"J. Headache Pain."},{"key":"10.1016\/j.biopha.2025.118044_bib177","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1468-2982.2005.01031.x","article-title":"Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs","volume":"26","author":"Cupini","year":"2006","journal-title":"Cephalalgia"},{"key":"10.1016\/j.biopha.2025.118044_bib178","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.nbd.2008.01.003","article-title":"Degradation of endocannabinoids in chronic migraine and medication overuse headache","volume":"30","author":"Cupini","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2025.118044_bib179","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/sj.npp.1301246","article-title":"Endocannabinoids in chronic migraine: CSF findings suggest a system failure","volume":"32","author":"Sarchielli","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2025.118044_bib180","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1177\/0333102414566862","article-title":"Effects of peripheral FAAH blockade on NTG-induced hyperalgesia--evaluation of URB937 in an animal model of migraine","volume":"35","author":"Greco","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/j.biopha.2025.118044_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105157","article-title":"Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine","volume":"147","author":"Greco","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2025.118044_bib182","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.phrs.2015.04.001","article-title":"Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive","volume":"97","author":"Sasso","year":"2015","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2025.118044_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114194","article-title":"Synergistic antinociceptive effects of concomitant NAAA and peripheral FAAH inhibition","volume":"357","author":"Mabou Tagne","year":"2022","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2025.118044_bib184","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.euroneuro.2015.04.001","article-title":"Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice","volume":"25","author":"Nozaki","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2025.118044_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104624","article-title":"FAAH inhibition as a preventive treatment for migraine: A pre-clinical study","volume":"134","author":"Greco","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2025.118044_bib186","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neuropharm.2014.11.024","article-title":"Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy","volume":"95","author":"Nasirinezhad","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118044_bib187","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.3390\/ijms23094665","article-title":"Effect of Fatty Acid Amide Hydrolase Inhibitor URB597 on Orofacial Pain Perception in Rats","volume":"23","author":"Zubrzycki","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118044_bib188","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejphar.2017.10.007","article-title":"In vitro and in vivo pharmacological characterization of ASP8477: A novel highly selective fatty acid amide hydrolase inhibitor","volume":"815","author":"Watabiki","year":"2017","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173194","article-title":"ASP8477, a fatty acid amide hydrolase inhibitor, exerts analgesic effects in rat models of neuropathic and dysfunctional pain","volume":"881","author":"Kiso","year":"2020","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib190","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/can.2020.0177","article-title":"Monoacylglycerol Lipase Inhibition Using JZL184 Attenuates Paw Inflammation and Functional Deficits in a Mouse Model of Inflammatory Arthritis","volume":"6","author":"Nass","year":"2021","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.biopha.2025.118044_bib191","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3390\/jcm11061479","article-title":"Clinical Evidence of Cannabinoids in Migraine: A Narrative Review","volume":"11","author":"Lo Castro","year":"2022","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.biopha.2025.118044_bib192","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.871187","article-title":"Medical Cannabis for the Treatment of Migraine in Adults: A Review of the Evidence","volume":"13","author":"Okusanya","year":"2022","journal-title":"Front Neurol."},{"key":"10.1016\/j.biopha.2025.118044_bib193","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/pm\/pnab245","article-title":"Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study","volume":"23","author":"Baraldi","year":"2022","journal-title":"Pain. Med"},{"key":"10.1016\/j.biopha.2025.118044_bib194","first-page":"e102","article-title":"Medical Cannabis in Patients with Chronic Pain: Effect on Pain Relief, Pain Disability, and Psychological aspects. A Prospective Non randomized Single Arm Clinical Trial","volume":"169","author":"Poli","year":"2018","journal-title":"Clin. Ter."},{"key":"10.1016\/j.biopha.2025.118044_bib195","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.31555","article-title":"The Utility of Cannabis-Based Medicine in Chronic Pain Management: A Case Report","author":"Maurer","year":"2022","journal-title":"Cureus 14"},{"key":"10.1016\/j.biopha.2025.118044_bib196","first-page":"4900","article-title":"The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress","volume":"16","author":"Parlar","year":"2018","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.biopha.2025.118044_bib197","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejphar.2005.10.043","article-title":"A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833","volume":"528","author":"Whiteside","year":"2005","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib198","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.pain.2009.02.018","article-title":"Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833","volume":"143","author":"Hu","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2025.118044_bib199","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/741303","article-title":"Cannabinoid receptor 2 protects against acute experimental sepsis in mice","volume":"2013","author":"Gui","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.biopha.2025.118044_bib200","first-page":"1","article-title":"M.E. Shahaboddin, A CB2 Receptor Agonist Reduces the Production of Inflammatory Mediators and Improves Locomotor Activity in Experimental Autoimmune Encephalomyelitis","volume":"11","author":"Parastouei","year":"2022","journal-title":"Rep. Biochem Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118044_bib201","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41401-022-01037-8","article-title":"CB2R agonist GW405833 alleviates acute liver failure in mice via inhibiting HIF-1\u03b1-mediated reprogramming of glycometabolism and macrophage proliferation","volume":"44","author":"Cai","year":"2023","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.biopha.2025.118044_bib202","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41401-019-0213-0","article-title":"Protective effects of specific cannabinoid receptor 2 agonist GW405833 on concanavalin A-induced acute liver injury in mice","volume":"40","author":"Huang","year":"2019","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.biopha.2025.118044_bib203","article-title":"Cannabinoid receptor subtype 2 (CB2R) agonist, GW405833 reduces agonist-induced Ca(2+) oscillations in mouse pancreatic acinar cells","volume":"6","author":"Huang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118044_bib204","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12640-025-00729-3","article-title":"Cannabidiol-Induced Autophagy Ameliorates Tau Protein Clearance","volume":"43","author":"Vrechi","year":"2025","journal-title":"Neurotox. Res"},{"key":"10.1016\/j.biopha.2025.118044_bib205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s10020-024-01012-5","article-title":"AM1241 inhibits chondrocyte inflammation and ECM degradation through the Nrf2\/HO-1 and NF-\u03baB pathways and alleviates osteoarthritis in mice","volume":"31","author":"Zou","year":"2025","journal-title":"Mol. Med"},{"key":"10.1016\/j.biopha.2025.118044_bib206","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3889\/oamjms.2019.194","article-title":"AM-1241 CB2 Receptor Agonist Attenuates Inflammation, Apoptosis and Stimulate Progenitor Cells in Bile Duct Ligated Rats","volume":"7","author":"Mahmoud","year":"2019","journal-title":"Open Access Maced. J. Med Sci."},{"key":"10.1016\/j.biopha.2025.118044_bib207","first-page":"597","article-title":"Cannabinoid Receptor-2 agonist AM1241 Attenuates Myocardial Ischemia-Reperfusion-Induced Oxidative Stress in Rats via Nrf2\/HO-1 Pathway","author":"Zhang","year":"2024","journal-title":"Med Princ. Pr. 33"},{"key":"10.1016\/j.biopha.2025.118044_bib208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11010-020-03828-1","article-title":"Pharmacological activation of CB2 receptor protects against ethanol-induced myocardial injury related to RIP1\/RIP3\/MLKL-mediated necroptosis","volume":"474","author":"Liu","year":"2020","journal-title":"Mol. Cell Biochem"},{"key":"10.1016\/j.biopha.2025.118044_bib209","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/fcp.12502","article-title":"The curative effect of cannabinoid 2 receptor agonist on functional failure and disruptive inflammation caused by intestinal ischemia and reperfusion","volume":"34","author":"Bayram","year":"2020","journal-title":"Fundam. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118044_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109398","article-title":"Promoted inhibition of TLR4\/miR-155\/ NFkB p65 signaling by cannabinoid receptor 2 agonist (AM1241), aborts inflammation and progress of hepatic fibrosis induced by thioacetamide","volume":"336","author":"Ali","year":"2021","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.biopha.2025.118044_bib211","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/10520295.2020.1758343","article-title":"Effects of cannabinoid receptor 2 synthetic agonist, AM1241, on bleomycin induced pulmonary fibrosis","volume":"96","author":"Parlar","year":"2021","journal-title":"Biotech. Histochem"},{"key":"10.1016\/j.biopha.2025.118044_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2024.103958","article-title":"Cannabinoid receptor 2 agonist AM1241 alleviates epileptic seizures and epilepsy-associated depression via inhibiting neuroinflammation in a pilocarpine-induced chronic epilepsy mouse model","volume":"130","author":"Cai","year":"2024","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.biopha.2025.118044_bib213","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eplepsyres.2016.08.011","article-title":"The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats","volume":"127","author":"de Carvalho","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.biopha.2025.118044_bib214","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0304-3959(01)00454-7","article-title":"CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain","volume":"96","author":"Clayton","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2025.118044_bib215","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1097\/j.pain.0000000000002314","article-title":"Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents","volume":"163","author":"Castro","year":"2022","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2025.118044_bib216","article-title":"Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn\u2019s Disease","volume":"3","author":"Yacyshyn","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.biopha.2025.118044_bib217","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14539","article-title":"Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)","volume":"35","author":"Chang","year":"2023","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.biopha.2025.118044_bib218","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.42510","article-title":"the R.-1 S. Group, Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis","volume":"75","author":"Spiera","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.biopha.2025.118044_bib219","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial","volume":"142","author":"Werth","year":"2022","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.biopha.2025.118044_bib220","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcf.2020.09.008","article-title":"Lenabasum JBT101-CF-001 Study Group, Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis","volume":"20","author":"Chmiel","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2025.118044_bib221","unstructured":"Shionogi, A Phase Ib\/IIa, Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Mild to Moderate Atopic Dermatitis, clinicaltrials.gov, 2018. \u3008https:\/\/clinicaltrials.gov\/study\/NCT00697710\u3009 (accessed March 23, 2025)."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225002380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225002380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:04:00Z","timestamp":1781823840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225002380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":221,"alternative-id":["S0753332225002380"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118044","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118044"}}